[1]傅淑宏,魏开华,李晓霞,等.胃腺癌患者粪便蛋白质的提取及初步质谱分析[J].现代检验医学杂志,2015,30(04):14-20.[doi:10.3969/j.issn.1671-7414.2015.04.004]
　FU Shu-hong,WEI Kai-hua,LI Xiao-xia,et al.Protein Extraction and Preliminary Research on Proteins in Stools from Patients with Gastric Adenocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(04):14-20.[doi:10.3969/j.issn.1671-7414.2015.04.004]
点击复制

胃腺癌患者粪便蛋白质的提取及初步质谱分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年04期
页码:
14-20
栏目:
论著
出版日期:
2015-08-10

文章信息/Info

Title:
Protein Extraction and Preliminary Research on Proteins in Stools from Patients with Gastric Adenocarcinoma
文章编号:
1671-7414(2015)04-014-07
作者:
傅淑宏1; 魏开华2; 李晓霞1; 张 拓2; 龚美亮1; 周 玉1; 李燕燕1; 白 洁1
1.解放军总医院南楼检验科,北京 100853;
2.北京蛋白质组研究中心,蛋白质组学国家重点实验室,北京 102206
Author(s):
FU Shu-hong1; WEI Kai-hua2; LI Xiao-xia1; ZHANG Tuo2;  GONG Mei-liang1; ZHOU Yu1; LI Yan-yan1; BAI Jie1
1.Department of Clinical Laboratory,Chinese PLA General Hospital,Beijing 100853,China;
2.Beijing Proteomics Research Center, State Key Laboratory of Proteomics,Beijing 102206,China
关键词:
粪便;  蛋白质;  胃腺癌;  质谱
分类号:
R735.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2015.04.004
文献标志码:
A
摘要:
目的 建立一个良好的粪便蛋白质提取、分析和鉴定的方法,为进一步探索消化系统疾病无创性诊治靶标提供新思路和奠定良好研究体系。方法 采用生理盐水、Tris-HCl和尿素缓冲液三种粪便蛋白质提取体系,处理健康人群、慢性萎缩性胃炎、胃腺癌术前、胃腺癌术后的粪便标本,通过SDS-PAGE进行比较,获得较好的粪便蛋白质提取方法。再利用液相串联质谱(1D LC-MS/MS)对提取的蛋白质进行初步分析。结果 生理盐水和Tris-HCl缓冲液提取粪便蛋白质的效率明显较尿素法高,损失少,是粪便蛋白质比较有效和合理的提取方法。不同人群来源的粪便中均含有丰富的蛋白质,正常人、胃腺癌手术前及术后鉴定到的蛋白质达一百多种,在组成和含量上个体差异明显。疾病与正常间、疾病治疗前后,粪便蛋白质指纹图谱变化大。胃腺癌术前粪便中含有大量的免疫球蛋白和角蛋白,同时也鉴定到了α1-抗胰蛋白酶,但在其术后和健康者粪便中未见到这一现象。结论 正常与胃癌、胃癌手术前与术后粪便蛋白质不仅有蛋白质种类的差异,而且相同蛋白质量的差异也相当明显。因此,利用蛋白质组学技术筛选人粪便中胃癌相关的蛋白质标志物有较强的可行性,但在未来的研究中需要差异分析结合定量质谱的方法进行。
Abstract:
Objective To set up a method of stools proteinextraction,analysis and identification in order to get the new noninvasive indicators of human digestive diseases.Methods The stools proteins,collected from healthy persons,the patients with atrophic gastritis,those who suffed from gastric carcinoma and postoperative patients with gastric carcinoma respectively,were extracted in three different ways including saline,Tris-HCl buffer and Urea buffer,the best way was selected by using SDS-PAGE,then a preliminary analysis of stools proteins was performed by 1D LC-MS/MS.Results The methods of saline and Tris-HCl buffer could getmore stools proteins than the method of urea.The proteins in stools from the healthy persons,the patients with atrophic gastritis,the patients with gastriccarcinoma and postoperative patients with gastric carcinoma were all abundant and more than one hundred.There was a significant difference in stools protein maps among the various populations.Alpha1-antitrypsin,a number of immunoglobulin and keratin were identified in the stools from patients with gastric carcinomabut not postoperative patients with gastric carcinoma and the healthy persons.Conclusions In this research,there was a significant difference in stools protein maps among the healthy persons,the patients with atrophic gastritis,the patients with gastric carcinoma and postoperative patients with gastric carcinoma,not only the composition of stools proteins,but also theabundance of same proteins.Therefore,using proteomics technologies to screening of the noninvasive indicators in human stools is viable.The study recommended that the noninvasive indicators in human stools should be identified with quantitative differences analysis combination of quality of mass spectrometer method in the future research.

参考文献/References:

[1] 白 洁,傅淑宏,蔡力力,等.我国现阶段粪便常规检查指标异常率调查分析[J].现代检验医学杂志,2008,23(5):89-91.
Bai J,Fu SH,Cai LL,et al.Investigation and analysis of the rateof abnormal index for stool for routine at present in China[J].J Mod Lab Med,2008,23(5):89-91.
[2] Verberkmoes NC,Russell AL,Shah M,et al.Shotgun metaproteomics of thehuman distal gut microbiota[J].ISME J,2009,3(2):179-189.
[3] Kim Y,Lee S,Park S,et al.Gastrointestinal tract ca-ncer screening using fecal carcinoembryonic antigen[J].Ann Clin Lab Sci,2003,33(1):32-38.
[4] 张健锋,毛振彪.粪便标志物检测在大肠癌筛查中的应用[J].国际肿瘤学杂志,2007,34(7):522-525.
Zhang JF,Mao ZB.Advance in application of screening for colorectalneoplasm by assaying exfoliated markers from feces[J].J Int Oncol,2007,34(7):522-525.
[5] 李伟伟,杨玉秀.联合检测粪便中k-ras与p53基因诊断大肠癌[J].胃肠病学和肝病学杂志,2007,16(2):184-186.
Li WW,Yang YX.Detection of k-ras and p53 mutations in faecal samples from patients with sporadic colorectal cancer[J].Chin J Gastroenterol Hepatol,2007,16(2):184-186.
[6] Ebert MP,Lamer S,Meuer J,et al.Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis[J].J Proteome Res,2005,4(2):586-590.
[7] Yoshihara T,Kadota Y,Yoshimura Y,et al.Proteo-mic alteration in gastric adenocarcinomas from Japanese patients[J].Mol Cancer,2006(5):75.
[8] Zou HZ,Harrington JJ,Sugumar A,et al.Detection of colorectal diseaseby stool defensin assay:an exploratory study[J].Clin Gastroenterol Hepatol,2007,5(7):865-868.
[9] Shastri YM,Povse N,Schroder O,et al.Comparison of a novel fecal marker-fecal tumor pyruvate kinase type M2(M2-PK)with fecal calprotectin in patients with inflammatory bowel disease:a prospective study[J].Clin Lab,2008,54(9/10):389-390.
[10] Pucci S,Bonanno E,Sesti F,et al.Clusterin in sto-ol:a newbiomarker for colon cancer screening?[J].Am J Gastroenterol,2009,104(11):2807-2815.
[11] Kumar Y,Tapuria N,Kirmani N,et al.Tumour M2-pyruvate kinase:a gastrointestinal cancer marker[J].Eur J Gastroenterol Hepatol,2007,19(3):265-276.
[12] Mulder SA,van-Leerdam ME,van-Vuuren AJ,et al.Tumor pyruvate kinaseisoenzyme type M2 and immunochemical fecal occult blood test:performance in screening for colorectal cancer[J].Eur J Gastroenterol Hepatol,2007,19(10):878-882.
[13] Haug U,Hundt S,Brenner H.Sensitivity and specificity of faecal tumourM2 pyruvate kinase for detection of colorectal adenomas in a large screening study[J].Br J Cancer,2008,99(1):133-135.
[14] Bosch LJW,Carvalho B,Fijneman RJA,et al.Mo-lecular tests for colorectal cancer screening[J].Clinical Colorectal Cancer,2011,10(1):8-23.
[15] 沈建根,林 洁,朱永良,等.克隆酶均相免疫技术测定胃癌患者血清和粪便P53蛋白的研究[J].中华检验医学杂志,2004,27(11):773-776.
Shen JG,Lin J,Zhu YL,et al.Establishment of cloned homogeneous immunoassay for detection of P53 protein in serum and stool samples from patients withgastric carcinoma[J].Chin J Lab Med,2004,27(11):773-776.
[16] Chen MH,Yip GW,Tse GM,et al.Expression of basal keratins and vimentin in breast cancers of Young Women correlates with adverst pathologic parameters[J].Mod Pathol,2008,21(10):1183-1191.
[17] Jang JS,Cho HY,Lee YJ,et al.The differential proteome profile of stomach cancer:identification of the biomarker candidates[J].Oncol Res,2004,14(10):491-499.
[18] 张秉琪,刘 馨,安煜致.肿瘤标志物临床手册[M].北京:人民军医出版社,2008:104.
Zhang BQ,Liu X,An YZ.The clinical manual of tumor markers[M].Beijing:People's Military Medical Press,2008:104.
[19] Wu W,Chung M.The gastric fluid proteome as a potential source of gastric cancer biomarkers[J].J Proteomics,2013(90):3-13.

备注/Memo

备注/Memo:
基金项目:北京市科委首都临床特色应用研究项目(Z121107005112009),蛋白质组学国家重点实验室开放课题(SKLP-O200907)。
作者简介:傅淑宏(1970-),女,大学本科,主管技师,主要从事实验室诊断及研究工作,E-mail:hongfs@163.com。
通讯作者:白 洁,E-mail:jiebai6907@sina.com。
更新日期/Last Update: 2015-08-10